Circulating Tumor Cells in Early Breast Cancer

Area of Science:

• Oncology
• Biomarkers
• Cancer Diagnostics

Background:

• Circulating tumor cells (CTCs) are rare in non-metastatic breast cancer, with initial clinical validity for detection being unrecognized.
• The CellSearch system, a CLIA-compliant cytological CTC detection device, was developed, enabling robust analysis.
• Early studies, including REMAGUS02 in 2008, indicated shorter distant metastasis-free survival in early breast cancer patients with detectable CTCs.

Purpose of the Study:

• To review the established clinical validity and prognostic significance of CTC detection in early breast cancer.
• To summarize data supporting CTC detection as a reliable biomarker for predicting relapse and survival outcomes.
• To highlight the potential of CTCs as a proliferation- and subtype-independent biomarker for metastasis in early breast cancer.

Main Methods:

• Review of clinical studies and meta-analyses on CTC detection in early breast cancer.
• Evaluation of data establishing CTC detection as a level-of-evidence 1 prognostic biomarker.
• Analysis of the CellSearch system's analytical validity and CLIA compliance.

Main Results:

• CTC detection is established as a level-of-evidence 1 prognostic biomarker in early breast cancer.
• Studies confirm CTC detection predicts local relapses, distant relapses, and overall survival.
• A significant association exists between CTC presence and shorter distant metastasis-free survival.

Conclusions:

• Circulating tumor cell detection is a validated prognostic biomarker in early breast cancer.
• CTC analysis offers valuable prognostic information independent of tumor proliferation and subtype.
• The review underscores the promise of CTC detection for improved patient management and outcome prediction.